Bone-Targeting Radiopharmaceuticals as Monotherapy or Combined With Chemotherapy in Patients With Castration-Resistant Prostate Cancer Metastatic to Bone

Autor: Rob ter Heine, John M. H. de Klerk, Rogier Lange, Jocye M. Van Dodewaard-de Jong, Alfons J.M. van den Eertwegh, Haiko J. Bloemendal, Henk M.W. Verheul, Esther W. Bouman-Wammes

Publikováno v: Clinical Genitourinary Cancer, 17, e281-e292
Bouman-Wammes, E W, de Klerk, J M H, Bloemendal, H J, Van Dodewaard-de Jong, J M, Lange, R, ter Heine, R, Verheul, H M W & Van den Eertwegh, A J M 2019, ' Bone-Targeting Radiopharmaceuticals as Monotherapy or Combined With Chemotherapy in Patients With Castration-Resistant Prostate Cancer Metastatic to Bone ', Clinical Genitourinary Cancer, vol. 17, no. 2, pp. e281-e292 . https://doi.org/10.1016/j.clgc.2018.11.014
Clinical Genitourinary Cancer, 17, 2, pp. e281-e292

Item does not contain fulltext In patients with metastatic castration-resistant prostate cancer, bone is the most common site for metastases. Because of their osteoblastic character, these lesions are very suitable for treatment with bone-seeking rad

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9576a2398bf7da9e4300f13aba91daa3
http://hdl.handle.net/2066/205220